Dec. 9 ASH Quick Takes: Kite, Principia, Blueprint, Precision and Rocket

Kite plans marketing applications for CD19 CAR T on pivotal MCL data
Kite Pharma Inc. reported a 93% best objective response rate including a 67% complete response rate -- secondary endpoints -- in 60 evaluable relapsed or refractory mantle cell lymphoma patients who received a single infusion of

Read the full 471 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers